Literature DB >> 11437765

Status epilepticus.

M G Chapman1, M Smith, N P Hirsch.   

Abstract

Status epilepticus is a medical emergency that requires rapid and vigorous treatment to prevent neuronal damage and systemic complications. Failure to diagnose and treat status epilepticus accurately and effectively results in significant morbidity and mortality. Cerebral metabolic decompensation occurs after approximately 30 min of uncontrolled convulsive activity, and the window for treatment is therefore limited. Therapy should proceed simultaneously on four fronts: termination of seizures; prevention of seizure recurrence once status is controlled; management of precipitating causes of status epilepticus; management of the complications. This article reviews current opinions about the classification, aetiology and pathophysiology of adult generalised convulsive status epilepticus and details practical management strategies for treatment of this life-threatening condition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437765     DOI: 10.1046/j.1365-2044.2001.02115.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  11 in total

1.  Sudden unexpected death in a mouse model of Dravet syndrome.

Authors:  Franck Kalume; Ruth E Westenbroek; Christine S Cheah; Frank H Yu; John C Oakley; Todd Scheuer; William A Catterall
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

2.  Status epilepticus.

Authors:  Ajith Cherian; Sanjeev V Thomas
Journal:  Ann Indian Acad Neurol       Date:  2009-07       Impact factor: 1.383

3.  Status epilepticus: current treatment strategies.

Authors:  Edward M Manno
Journal:  Neurohospitalist       Date:  2011-01

Review 4.  Neuromuscular blocking drugs in the critically ill.

Authors:  C Welhengama; A Hall; J M Hunter
Journal:  BJA Educ       Date:  2021-03-19

5.  Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus.

Authors:  Kensuke Nakamura; Ryota Inokuchi; Hiroaki Daidoji; Hiromu Naraba; Tomohiro Sonoo; Hideki Hashimoto; Kurato Tokunaga; Takahiro Hiruma; Kent Doi; Naoto Morimura
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

6.  Levetiracetam vs. Fosphenytoin for Second-Line Treatment of Status Epilepticus: Propensity Score Matching Analysis Using a Nationwide Inpatient Database.

Authors:  Kensuke Nakamura; Hiroyuki Ohbe; Hiroki Matsui; Yuji Takahashi; Aiki Marushima; Yoshiaki Inoue; Kiyohide Fushimi; Hideo Yasunaga
Journal:  Front Neurol       Date:  2020-07-02       Impact factor: 4.003

7.  Anxiolytic and Antiepileptic Properties of the Aqueous Extract of Cissus quadrangularis (Vitaceae) in Mice Pilocarpine Model of Epilepsy.

Authors:  Fleur C O Moto; Aren Arsa'a; Gwladys T Ngoupaye; Germain S Taiwe; Jacqueline S K Njapdounke; Antoine K Kandeda; Gisele C N Nkantchoua; Jean P Omam Omam; Simon Pale; Nadege E Kouemou; Espoir R Ayissi Mbomo; David B Pahaye; Lucie Ojong; Veronique Mairara; Elisabeth Ngo Bum
Journal:  Front Pharmacol       Date:  2018-07-17       Impact factor: 5.810

8.  Changes in Real-world Practice Patterns of Antiepileptic Drugs for Status Epilepticus: A Nationwide Observational Study in Japan.

Authors:  Kensuke Nakamura; Hiroyuki Ohbe; Hiroki Matsui; Yuji Takahashi; Aiki Marushima; Yoshiaki Inoue; Kiyohide Fushimi; Hideo Yasunaga
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-01-31       Impact factor: 1.742

9.  Expression and functional analysis of lncRNAs in the hippocampus of immature rats with status epilepticus.

Authors:  Jing Gan; Lingyi Huang; Yi Qu; Rong Luo; Qianyun Cai; Fengyan Zhao; Dezhi Mu
Journal:  J Cell Mol Med       Date:  2019-11-18       Impact factor: 5.310

10.  Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial.

Authors:  Kensuke Nakamura; Aiki Marushima; Yuji Takahashi; Akio Kimura; Masahiro Asami; Satoshi Egawa; Junya Kaneko; Yutaka Kondo; Chikara Yonekawa; Eisei Hoshiyama; Takeshi Yamada; Kazushi Maruo; Yoshiaki Inoue
Journal:  Trials       Date:  2021-05-02       Impact factor: 2.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.